GSK plc announced the following changes to its Board and Committees, which took effect immediately following the demerger of the Consumer Healthcare business on 18 July 2022 (the Demerger): Charles Bancroft has succeeded Vindi Banga as Senior Independent Non-Executive Director. Mr. Bancroft has also been appointed a member of the Remuneration Committee. Urs Rohner has been appointed a member of the Audit & Risk Committee.

Dr. Anne Bealhas been appointed a member of the Remuneration and Nominations & Corporate Governance committees. Dr. Vishal Sikkawho joined the Board on 18 July 2022 has been appointed a member of the Corporate Responsibility Committee. In addition, Dr. Sikka will attend Audit & Risk Committee meetings to support the Committee's oversight of GSK's Digital and Technology programme.

Vindi Bangaand Dame Vivienne Cox stepped down from the GSK Board upon their appointments to the Haleon plc Board effective on Demerger. Lynn Elsenhansretired from the Board effective from the Demerger.